Adults and children over 6 years. Reduction of nasal edema in acute mucositis, vasomotor mucositis and allergic rhinitis. Facilitating the outflow of secretions in the inflammation of the paranasal sinuses and in the inflammation of the ear canal of the middle ear connected to the common cold.
Composition:
1 ml of solution contains 1 mg of Xylometazoline hydrochloride. Sudafed XyloSpray contains benzalkonium chloride.
Action:
Sympathomimetic for topical use, acting on α-adrenergic receptors. Shrinks the blood vessels, thus reducing swelling of the mucous membrane. The onset of action usually occurs within 5-10 min after administration. The reduction of mucosal edema makes breathing easier through the nose and facilitates the outflow of secretions. Sodium hyaluronate, contained in the preparation Sudafed XyloSpray HA, protects and moisturizes the nasal mucosa.
Contraindications:
Hypersensitivity to xylometazoline or other components of the drug. Dry atrophic rhinitis. Do not use in patients after removal of the pituitary gland and after other surgical procedures involving the exposition of the dura mater. Do not use in infants and children under the age of 6 years.
Precautions:
It can only be used after careful consideration of the benefit-risk ratio of its use in patients: those who are treated with MAOIs or other medicines that may cause high blood pressure; with elevated intraocular pressure, in particular due to narrow-angle glaucoma; with severe cardiovascular diseases (eg ischemic heart disease, hypertension); with phaeochromocytoma; with metabolic disorders (eg hyperthyroidism, diabetes); with the growth of the prostate gland. The drug should be administered with extreme caution to patients with hypersensitivity to adrenomimetic substances, manifested as insomnia, tremor, dizziness, cardiac arrhythmias and increased blood pressure. The use of xylometazoline in doses higher than recommended or for a longer period than recommended (5 days) may lead to reactive nasal congestion, drug-induced rhinitis, dry atrophic rhinitis and to narrowing of the upper respiratory tract, so that the patient returns again for taking the drug, and in some cases it is used for a long time. Benzalkonium chloride contained in Sudafed XyloSpray may cause irritation of the nasal mucosa.
Pregnancy and lactation:
The drug should not be used in pregnant women and during breastfeeding (insufficient data).
Side effects:
Often, after discontinuation of the drug, mucosal edema (reactive hyperaemia) may increase. Uncommon: Systemic sympathomimetic effects (eg palpitations, increased heart rate, increased blood pressure). Rare: nausea, visual disturbances, allergic reactions, headache, insomnia or fatigue. In addition, you may experience symptoms of irritation (burning or dryness of the nasal mucosa), sneezing, especially in sensitive patients. Long-term or frequent use, as well as administration in doses higher than recommended, may lead to reactive hyperemia with drug-induced rhinitis; this effect may occur after 5 days of treatment and if continued, may lead to dry atrophic rhinitis.
Dosage:
Intranasally. Adults and children over 6 years: depending on the needs, after one dose of the drug to each nostril up to three times a day. Do not exceed the recommended dose. The drug should not be used for more than 5 days; repeated application can be started after a few days break.
(C)
